Implementation of a New Strategy to Identify HNPCC Patients
Recruitment status was Recruiting
The purpose of this study is to compare two different strategies to implement a new method to identify patients with HNPCC, which appeared cost-effective and feasible. The effectiveness, costs and feasibility of both of the implementation strategies will be assessed.
Hereditary Nonpolyposis Colorectal Cancer
Behavioral: Education for professionals
Behavioral: Distribution of educational materials
Behavioral: Feedback for professionals
Behavioral: Reminders for professionals
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
|Official Title:||Cost Effectiveness of Two Different Implementation Procedures to Change Clinicians Practice Roles in the Detection of Hereditary Colorectal Cancer|
- Efficacy of inclusion of eligible CRC-patients for MSI testing by pathologists.
- Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons.
- Experiences with and acceptance of changed physician practice roles by patients and clinicians.
- Cost efficacy of the implementation procedures.
|Study Start Date:||September 2005|
|Estimated Study Completion Date:||July 2007|
The Radboud University Nijmegen Medical Centre developed a new method to identify patients with HNPCC. This method appeared cost-effective and feasible. Using this new method 70% of the HNPCC patients will be identified as compared to less than 30% when the current method is used. However, this new method does not implement itself; large gaps exists between best evidence and daily practice. This study will compare an intensive strategy, consisting of distribution of educational materials, education, feedback and reminders, with a minimal strategy, only consisting of distribution of a critical care pathway. The aim is to find the most cost-effective strategy to implement the new method to identify patients with HNPCC in the Netherlands.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00141466
|Contact: Lucy I Overbeek, MScemail@example.com|
|Contact: Nicoline Hoogerbrugge, MD PhDfirstname.lastname@example.org|
|Jeroen Bosch Ziekenhuis||Recruiting|
|Contact: Stan J Ketelaars, MD|
|Meander Medisch Centrum||Recruiting|
|Contact: Els JM Ahsmann, MD PhD|
|Contact: Jos Meijer, MD|
|Den Haag, Netherlands|
|Contact: Paul Blok, MD PhD|
|Pathologie laboratorium voor Dordrecht||Recruiting|
|Contact: Pieter J Westenend, MD PhD|
|Stichting laboratoria voor pathologische anatomie en medische microbiologie||Recruiting|
|Contact: Ineke van Lijnschoten, MD PhD|
|Laboratorium voor pathologie Oost-Nederland||Recruiting|
|Contact: Sietske Riemersma, MD|
|Contact: Ton Tiebosch, MD PhD|
|Contact: Cilia M Ferrier, MD PhD|
|Laboratorium Volksgezondheid Friesland||Recruiting|
|Contact: Joris J Grond, MD PhD|
|Canisius Wilhelmina Ziekenhuis||Recruiting|
|Contact: Erik Thunnissen, MD PhD|
|Medisch Centrum Rijnmond Zuid||Recruiting|
|Contact: Sonja Henzen, MD PhD|
|St. Elisabeth Ziekenhuis||Recruiting|
|Contact: Anneke van der Wurff, MD PhD|
|Principal Investigator:||Nicoline Hoogerbrugge, MD PhD||Department of Human Genetics, Radboud University Nijmegen Medical Center|
|Principal Investigator:||Rosella P Hermens, MSc PhD||Center of Quality of Care Research, Radboud University Nijmegen Medical Center|